Memantine

From Wikipedia, the free encyclopedia

Template:Short description Template:Cs1 config Template:DMCA Template:Short description Page Template:Infobox drug/styles.css has no content.

Page Module:Infobox/styles.css has no content.

Memantine
Lua error in package.lua at line 80: module 'Module:InfoboxImage/data' not found.
Lua error in package.lua at line 80: module 'Module:InfoboxImage/data' not found.
Clinical data
Trade namesAxura, Ebixa, Namenda, others[1][2]
Other names1-Amino-3,5-dimethyladamantane; 3,5-Dimethyladamantan-1-amine; Dimethyladamantanamine; DMAA; D145; D-145
AHFS/Drugs.comMonograph
MedlinePlusa604006
License dataPage Template:Plainlist/styles.css has no content.
Pregnancy
category		Page Template:Plainlist/styles.css has no content.
  • AU: B2
Routes of
administration		By mouth
Drug classNMDA receptor antagonist
ATC codePage Template:Plainlist/styles.css has no content.
Legal status
Legal statusPage Template:Plainlist/styles.css has no content.
Pharmacokinetic data
Bioavailability100%[8][9]
Protein binding45%[8][9]
MetabolismMinimal[9]
Metabolites• Memantine glucuronide[8][9]
• 6-Hydroxymemantine[8][9]
• 1-Nitrosomemantine[8][9]
Elimination half-life60–80 hours[8][9]
ExcretionUrine (57–82% unchanged)[8][9]
Identifiers
  • 3,5-dimethyltricyclo[3.3.1.13,7]decan-1-amine
CAS NumberPage Template:Plainlist/styles.css has no content.
PubChem CIDPage Template:Plainlist/styles.css has no content.
PubChem SIDPage Template:Plainlist/styles.css has no content.
IUPHAR/BPSPage Template:Plainlist/styles.css has no content.
DrugBankPage Template:Plainlist/styles.css has no content.
ChemSpiderPage Template:Plainlist/styles.css has no content.
UNIIPage Template:Plainlist/styles.css has no content.
KEGGPage Template:Plainlist/styles.css has no content.
ChEBIPage Template:Plainlist/styles.css has no content.
ChEMBLPage Template:Plainlist/styles.css has no content.
NIAID ChemDBPage Template:Plainlist/styles.css has no content.
PDB ligandPage Template:Plainlist/styles.css has no content.
E number{{#property:P628}}
CompTox Dashboard (EPA)Page Template:Plainlist/styles.css has no content.
ECHA InfoCard{{#property:P2566}}Template:EditAtWikidata
Chemical and physical data
FormulaC12H21N
Molar mass179.307 g·mol−1
3D model (JSmol)Page Template:Plainlist/styles.css has no content.
  • NC12CC3CC(C)(C1)CC(C)(C3)C2

  • as HCl: Cl.NC12CC3CC(C)(C1)CC(C)(C3)C2
  • InChI=1S/C12H21N/c1-10-3-9-4-11(2,6-10)8-12(13,5-9)7-10/h9H,3-8,13H2,1-2H3 checkY
  • Key:BUGYDGFZZOZRHP-UHFFFAOYSA-N checkY

  • as HCl: InChI=1S/C12H21N.ClH/c1-10-3-9-4-11(2,6-10)8-12(13,5-9)7-10;/h9H,3-8,13H2,1-2H3;1H
  • Key:LDDHMLJTFXJGPI-UHFFFAOYSA-N
Data page
Template:Infobox drug/data page link
Page Template:Nobold/styles.css has no content.  (verify)

Memantine, sold under the brand name Namenda among others, is a medication used to slow the progression of moderate-to-severe Alzheimer's disease.[10][11][8] It is taken by mouth.[10][8]

Common side effects include headache, constipation, sleepiness, and dizziness.[10][11] Severe side effects may include blood clots, psychosis, and heart failure.[11] It is believed to work by acting on NMDA receptors, working as a pore blocker of these ion channels.[8][10]

Memantine was first discovered in 1963.[8][12][13] It was approved for medical use in Germany in 1989, in the European Union in 2002, and in the United States in 2003.[13][10][14] It is available as a generic medication.[11] In 2023, it was the 145th most commonly prescribed medication in the United States, with more than 3 million prescriptions.[15][16]

Medical uses

Alzheimer's disease and dementia

Memantine is used to treat moderate-to-severe Alzheimer's disease, especially for people who are intolerant of or have a contraindication to AChE (acetylcholinesterase) inhibitors.[17][18] One guideline recommends memantine or an AChE inhibitor be considered in people in the early-to-mid stage of dementia.[19]

Memantine has been associated with a modest improvement;[20] with small positive effects on cognition, mood, behavior, and the ability to perform daily activities in moderate-to-severe Alzheimer's disease.[21][22] There does not appear to be any benefit in mild disease.[23]

Memantine when added to donepezil in those with moderate-to-severe dementia resulted in "limited improvements" in a 2017 review.[24] The UK National Institute for Clinical Excellence (NICE) issued guidance in 2018 recommending consideration of the combination of memantine with donepezil in those with moderate-to-severe dementia.[25]

Radiation therapy

Memantine has been recommended for use by professional organization consensus to prevent neurocognitive decline after whole brain radiotherapy.[26]

Adverse effects

Memantine is, in general, well tolerated.[20] Common adverse drug reactions (≥1% of people) include confusion, dizziness, drowsiness, headache, insomnia, agitation, and/or hallucinations. Less common adverse effects include vomiting, anxiety, hypertonia, cystitis, and increased libido.[20][27]

Like many other NMDA receptor antagonists, memantine behaves as a dissociative anesthetic at supratherapeutic doses.[28] Despite isolated reports, recreational use of memantine is rare due to the drug's long duration and limited availability.[28] Additionally, memantine seems to lack effects such as euphoria or hallucinations.[29]

Memantine appears to be generally well tolerated by children with autism spectrum disorder.[30]

Pharmacology

Pharmacodynamics

Memantine is an uncompetitive NMDA receptor antagonist, with an IC50 binding affinity of ~500-1,000 nM (0.5-1 μM),[31] but displays higher potency at extrasynaptic NMDA receptors (IC50 = ~22 nM),[31] suggesting preferential inhibition of pathological glutamatergic signaling.

Memantine also exhibits activity at several other receptors:

  • Dopamine D2High receptor agonist (IC50 affinity = ~137-917 nM);[32] increases dopaminergic activity in the prefrontal cortex and striatum.[33][34] Memantine may inhibit the release of prolactin through D2 agonism, based on studies from isolated anterior pituitary cells.[32]
  • Alpha 7 nicotinic acetylcholine receptor antagonist (IC50 affinity = 340nM-5,000 nM or 0.34-5 μM).[35][36]
  • 5-HT3 receptor receptor antagonist (IC50 affinity = ~1,000 nM).[37][32]
  • Believed to block NMDA overactivation and restore cognitive dysfunction without significantly impairing normal synaptic transmission.
  • No meaningful acetylcholinesterase (AChE) inhibition.

Glutamatergic

A dysfunction of glutamatergic neurotransmission, manifested as neuronal excitotoxicity, is hypothesized to be involved in the etiology of Alzheimer's disease. Targeting the glutamatergic system, specifically ionotropic glutamate NMDA receptors, offers a novel approach to treatment in view of the limited efficacy of existing drugs targeting the cholinergic system.[38]

Memantine is a low-affinity voltage-dependent uncompetitive antagonist at glutamatergic NMDA receptors[39][40] with an IC50 binding affinity of ~500-1,000 nM (0.5-1 μM),[31] but displays higher potency at extrasynaptic NMDA receptors (~22 nM).[31]

Magnesium (Mg2+), the natural NMDA channel blocker, has an apparent dissociation constant (Ka/Ki) of roughly 2-3 mM (2,000,000-3,000,000 nM), making memantine ~1000x stronger at NMDA than Mg2+. By binding to the NMDA receptor with a higher affinity than Mg2+, memantine is able to inhibit the prolonged influx of Ca2+ ions, particularly from extrasynaptic receptors, which forms the basis of neuronal excitotoxicity. The low affinity, uncompetitive nature, and rapid off-rate kinetics of memantine at the level of the NMDA receptor channel, however, preserve the function of the receptor at synapses, as it can still be activated by physiological release of glutamate following depolarization of the postsynaptic neuron.[41][42][43] The interaction of memantine with NMDA receptors plays a major role in the symptomatic improvement that the drug produces in Alzheimer's disease. However, there is no evidence yet that memantine's ability to protect against extrasynaptic NMDA receptor-mediated excitotoxicity has a disease-modifying effect in Alzheimer's disease, although this has been suggested in animal models.[42]

Serotonergic

Memantine acts as a non-competitive antagonist of the serotonin 5-HT3 receptor, with a potency similar to that for the NMDA receptor.[37][44] Many 5-HT3 receptor antagonists function as antiemetics, however the clinical significance of this anti-serotonergic activity of memantine in Alzheimer's disease is unknown.

Cholinergic

Memantine acts as a non-competitive antagonist at the α7 nicotinic acetycholine receptor[36] (IC50 affinity = 340nM-5,000nM[45] or 0.34-5 μM). Several studies have observed that Memantine's antagonism at nAChRs is higher than both its affinity to NMDA and 5-HT3 receptors,[45][46] but this may be difficult to ascertain with accuracy due to rapid desensitization of nAChRs.

Antagonism of α7 nAChRs may contribute to the initial worsening of cognitive function during early Memantine treatment. Nicotinic acetylcholine receptor, specifically α7 nAChR, upregulate quickly in response to antagonism, which could explain the possible cognitive-enhancing effects of Memantine.[47][48][45] It has been shown that the number of nicotinic receptors in the brain are reduced in Alzheimer's disease, even in the absence of a general decrease in the number of neurons, and nicotinic receptor agonists are viewed as interesting targets for anti-Alzheimer drugs.[49]

Dopaminergic

Memantine has been shown to act as an agonist of dopamine D2High receptor with equal or slightly higher affinity than to NMDA receptors[32] (D2 IC50 affinity = ~137-917 nM).[32] In another study, Memantine was shown to increase dopaminergic activity in the prefrontal cortex and striatum of mice.[50]

At least one study questions the relevance of Memantine's D2 receptor action, suggesting a low Ki value.[51]

Sigmaergic

Memantine acts as a weak agonist of the sigma σ1 receptor with low affinity (Ki = 2,600nM or 2.6 μM).[52] Due to this low affinity, therapeutic concentrations of memantine are most likely too low to have any sigmaergic effect as a typical therapeutic dose is 20 mg. The consequences of sigma activity would be unclear, as the role of sigma receptors in general is currently not very well understood. However, excessive doses of memantine taken for recreational purposes, which are many times greater than prescribed doses, may indeed activate this receptor.[53]

Other actions

Memantine does not appear to inhibit or induce several cytochrome P450 enzymes including CYP3A4/5, CYP1A2, CYP2D6, and CYP2C9.[8] It also does not inhibit CYP2A6 or CYP2E1.[9] However, it might have a small effect on CYP2B6.[8]

Pharmacokinetics

Absorption

The oral bioavailability of memantine is 100%.[8][9] Time to peak levels of memantine are 3 to 7 hours.[8][9] Food has no influence on the rate of absorption.[8][9] Memantine exposure is linear over a dose range of 10 to 40 mg.[8] Peak levels after a single 20 mg dose were found to be 24 to 29 μg/L (0.13–0.16 μmol/L or μM).[8] Steady-state levels of memantine with 20 mg/day are in the range of 0.5 to 1.0 μM.[9]

Distribution

Memantine has a relatively high volume of distribution (Vd) of 9 to 11 L/kg.[8][9] It easily crosses biological membranes, is widely distributed throughout the body, and crosses the blood–brain barrier into the central nervous system.[9] The drug is transported across the blood–brain barrier by the organic cation transporter novel 1 (OCTN1).[8] The plasma protein binding of memantine is 45% and is described as very low and not clinically significant.[8][9] Because of its low plasma protein binding, it is unlikely to interact with other highly protein-bound drugs such as warfarin or digoxin.[9]

Metabolism

Memantine does not undergo extensive metabolism.[9] It is negligibly metabolized by the cytochrome P450 enzymes.[8][9] As a result, it has a decreased potential for drug interactions.[9] Metabolites of memantine include memantine glucuronide, 6-hydroxymemantine, and 1-nitrosomemantine, all of which show minimal activity as NMDA receptor antagonists.[8][9]

Elimination

Memantine is eliminated primarily in urine, with 57 to 82% excreted in urine unchanged.[8][9] Its elimination half-life is 60 to 80 hours.[8][9] The renal clearance of memantine is dependent on urinary pH.[8][9] More alkaline urine slows the elimination of memantine, whereas more acidic urine accelerates its elimination.[8][9]

Chemistry

Memantine, also known as 3,5-dimethyl-1-aminoadamantane, is an adamantane derivative and is closely structurally related to amantadine (1-aminoadamantane) and other adamantane derivatives.[8][54][55][56]

The synthesis of memantine has been described.[8]

History

Script error: No such module "Labelled list hatnote".

Memantine was first synthesized, patented, and described by Eli Lilly and Company in 1963 as an anti-diabetic agent, but it was ineffective at lowering blood sugar.[8][12][13][57][58] By 1972, it was discovered to have central nervous system (CNS) activity, and was developed by Merz for treatment of neurological diseases, such as Parkinson's disease.[8][12] Memantine was first studied in the treatment of Alzheimer's disease in 1986.[13][14] The drug was first marketed for dementia in 1989 in Germany under the name Axura.[8][14][12]

It was not discovered to act as an NMDA receptor antagonist until 1989, after clinical trials had initiated.[8][12][59] Prior to this, it was theorized to directly and/or indirectly modulate the dopaminergic, noradrenergic, and serotonergic systems.[12][60][61][62] However, these actions were later realized to occur at 100-fold higher concentrations than those achieved therapeutically and hence are unlikely to be involved in its effects.[12][60][62]

In the United States, some CNS activities were discovered at Children's Hospital of Boston in 1990, and Children's licensed patents covering uses of memantine outside the field of ophthalmology to Neurobiological Technologies (NTI) in 1995.[63] In 1998, NTI amended its agreement with Children's to allow Merz to take over development.[64]

In 2000, Merz partnered with Forest to develop the drug for Alzheimer's disease in the United States under the brand name Namenda.[8][14] In 2000, Merz partnered with Suntory for the Japanese market and with Lundbeck for other markets including Europe;[65] the drug was originally marketed by Lundbeck under the name Ebixa.[14] Memantine was approved in the European Union in 2002 and in the United States in 2003.[8][13]

Sales of the drug reached $1.8 billion for 2014.[8][66] The cost of Namenda was $269 to $489 a month in 2012.[67]

In February 2014, as the July 2015 patent expiration for memantine neared, Actavis, which had acquired Forest, announced that it was launching an extended release (XR) form of memantine that could be taken once a day instead of twice a day as needed with the then-current "immediate release" (IR) version, and that it intended to stop selling the IR version in August 2014 and withdraw the marketing authorization. This is a tactic to thwart generic competition called product hopping. However the supply of the XR version ran short, so Actavis extended the deadline until the fall. In September 2014 the attorney general of New York, Eric Schneiderman, filed a lawsuit to compel Actavis to keep selling the IR version on the basis of antitrust law.[68][69]

In December 2014, a judge granted New York State its request and issued an injunction, preventing Actavis from withdrawing the IR version until generic versions could launch. Actavis appealed and in May a panel of the Second Circuit Court of Appeals upheld the injunction, and in June Actavis asked that its case be heard by the full Second Circuit panel.[70][71] In August 2015, Actavis' request was denied.[72]

Society and culture

Recreational use

Recreational use of memantine at supratherapeutic doses has been reported.[73] It is a weak NMDA receptor antagonist and is reported to produce dissociative and phencyclidine (PCP)-like effects in animals and humans at sufficiently high doses.[73][74][75] Even therapeutic doses have been found to produce mild dissociative-like effects in clinical studies.[73] In any case, the very long duration of action of memantine (>40 hours) has likely limited its misuse potential.[73] Recreational use of the related drug amantadine has similarly been reported.[73]

A study examining self-reported use of memantine on the social network Reddit showed that the drug was used both recreationally and as a nootropic, but also that it was misused in various illnesses as self-medication without strong scientific basis.[76]

Brand names

As of August 2017, memantine is marketed under many brand names worldwide including Abixa, Adaxor, Admed, Akatinol, Alceba, Alios, Almenta, Alois, Alzant, Alzer, Alzia, Alzinex, Alzixa, Alzmenda, Alzmex, Axura, Biomentin, Carrier, Cogito, Cognomem, Conexine, Cordure, Dantex, Demantin, Demax, Dementa, Dementexa, Ebitex, Ebixa, Emantin, Emaxin, Esmirtal, Eutebrol, Evy, Ezemantis, Fentina, Korint, Lemix, Lindex, Lindex, Lucidex, Manotin, Mantine, Mantomed, Marbodin, Mardewel, Marixino, Maruxa, Maxiram, Melanda, Memabix, Memamed, Memando, Memantin, Memantina, Memantine, Mémantine, Memantinol, Memantyn, Memanvitae, Memanxa, Memanzaks, Memary, Memax, Memexa, Memigmin, Memikare, Memogen, Memolan, Memorel, Memorix, Memotec, Memox, Memxa, Mentikline, Mentium, Mentixa, Merandex, Merital, Mexia, Mimetix, Mirvedol, Modualz, Morysa, Namenda, Nemdatine, Nemdatine, Nemedan, Neumantine, Neuro-K, Neuroplus, Noojerone, Pertam, Polmatine, Prilben, Pronervon, Ravemantine, Talentum, Timantila, Tingreks, Tonibral, Tormoro, Valcoxia, Vilimen, Vivimex, Witgen, Xapimant, Ymana, Zalatine, Zemertinex, Zenmem, Zenmen, and Zimerz.[1]

It is marketed in some countries as a combination drug with donepezil (memantine/donepezil) under the brand names Namzaric, Neuroplus Dual, and Tonibral MD.[1]

Research

Psychiatric disorders

Memantine has been studied and used off-label in the treatment of a variety of psychiatric disorders.[77] These include depression, bipolar disorder, schizophrenia, obsessive–compulsive disorder (OCD), substance misuse, pervasive developmental disorders (PDDs), and binge eating disorder (BED).[77] A 2008 systematic review concluded that although it was promising for such uses, memantine could not be recommended for such indications due to inadequate data.[77]

Memantine does not appear to be effective in the treatment of unipolar major depression or bipolar depression on the basis of systematic reviews and meta-analyses, including a 2021 Cochrane review.[78][79][80][81][82] However, a 2022 systematic review and meta-analysis concluded that memantine was significantly effective in the treatment of depressive symptoms in various psychiatric disorders, although with a very small effect size (Hedges' g = -0.17).[83]

There are likewise limited data to support memantine in the treatment of schizophrenia based on systematic reviews and meta-analyses.[84][85] However, a 2019 systematic review and meta-analysis reported that memantine was effective in the treatment of the negative and cognitive symptoms of schizophrenia with medium to large effect sizes.[86]

Parkinson's disease

Memantine has been studied in the treatment of Parkinson's disease since the early 1970s.[13][12][87][88][89] Whereas the related drug amantadine is approved for the treatment of Parkinson's disease and has been since the early 1970s,[55] memantine is not approved for the treatment of Parkinson's disease as of 2024.[90] However, it has been said that memantine, along with amantadine, has been widely used as an antiparkinsonian agent since at least 1994.[87]

Although amantadine and memantine have fairly similar pharmacology, it has been said that memantine does not share the antidyskinetic effects of amantadine.[91][92] However, findings are conflicting, and some data suggest that memantine may also have antidyskinetic effects.[93][94][95] Similarly to amantadine and dopamine receptor agonists, memantine reverses haloperidol-induced catalepsy and monoamine depletion-induced sedation in animals.[91][96] Memantine has been found to reduce bradykinesia and resting tremor in people with Parkinson's disease.[91][92] Memantine and amantadine are said to have moderate anti-akinetic effects in the treatment of Parkinson's disease.[87][97] The doses of memantine used for Parkinson's disease are about 5- to 10-fold lower than those of amantadine, which has been attributed to greater potency of memantine.[87]

As of 2022, a phase 3 clinical trial is studying the potential of memantine as disease-modifying treatment for Parkinson's disease that might slow progression of the disease.[98][99][100] It is specifically theorized to act by inhibiting cell-to-cell transmission of α-synuclein.[98][99]

Besides Parkinson's disease, memantine has been studied in the treatment of Parkinson's disease dementia (PDD) and dementia with Lewy bodies (DLB).[101][102][103]

Apathy

Apathy is a disorder of diminished motivation characterized by diminished interest and activity.[104][105] Systematic reviews and meta-analyses published from 2016 to 2022 have found that memantine is not effective in the treatment of apathy in Alzheimer's disease and other dementias.[106][107][108] However, another 2022 review reported that it was effective.[109]

Long COVID

Memantine, along with amantadine, is being studied and used off-label in the treatment long COVID.[110][111]

Catatonia

Memantine, along with amantadine, has been reported to be effective in the treatment of catatonia in case reports and case series.[112][113][114]

Autism spectrum disorder

There is no evidence that memantine improves symptoms of autism spectrum disorder. A 2024 meta-analysis of NMDA antagonists (including memantine) found no benefit over placebo on core or associated symptoms and more adverse events,[115] while a 2022 review concluded the effect on core symptoms is uncertain.[116]

References

Page Template:Reflist/styles.css has no content.

  1. ^ a b c Page Module:Citation/CS1/styles.css has no content."International brands for memantine". Drugs.com. Archived from the original on 25 April 2019. Retrieved 7 August 2017.
  2. ^ Page Module:Citation/CS1/styles.css has no content.Apotheker-Verein S (2004). Index Nominum: International Drug Directory. Medpharm Scientific Publishers. p. 753. ISBN 978-3-88763-101-7. Retrieved 12 September 2024.
  3. ^ Page Module:Citation/CS1/styles.css has no content.Anvisa (31 March 2023). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in português do Brasil). Diário Oficial da União (published 4 April 2023). Archived from the original on 3 August 2023. Retrieved 16 August 2023.
  4. ^ Page Module:Citation/CS1/styles.css has no content."Ebixa 10 mg film-coated tablets Summary of Product Characteristics (SmPC)". (emc). 13 December 2021. Retrieved 2 May 2024.
  5. ^ Page Module:Citation/CS1/styles.css has no content."Namenda- memantine hydrochloride tablet; Namenda- memantine hydrochloride kit". DailyMed. 1 November 2018. Retrieved 2 May 2024.
  6. ^ Page Module:Citation/CS1/styles.css has no content."Namenda XR- memantine hydrochloride capsule, extended release; Namenda XR- memantine hydrochloride kit". DailyMed. 15 November 2019. Retrieved 2 May 2024.
  7. ^ Page Module:Citation/CS1/styles.css has no content."Axura EPAR". European Medicines Agency (EMA). 17 May 2002. Retrieved 27 February 2024.
  8. ^ a b c d e f g h i j k l m n o p q r s t u v w x y z aa ab ac ad ae af ag ah ai aj Page Module:Citation/CS1/styles.css has no content.Alam S, Lingenfelter KS, Bender AM, Lindsley CW (September 2017). "Classics in Chemical Neuroscience: Memantine". ACS Chemical Neuroscience. 8 (9): 1823–1829. doi:10.1021/acschemneuro.7b00270. PMID 28737885.
  9. ^ a b c d e f g h i j k l m n o p q r s t u v w x y Page Module:Citation/CS1/styles.css has no content.Schmitt F, Ryan M, Cooper G (February 2007). "A brief review of the pharmacologic and therapeutic aspects of memantine in Alzheimer's disease". Expert Opinion on Drug Metabolism & Toxicology. 3 (1): 135–141. doi:10.1517/17425255.3.1.135. PMID 17269900.
  10. ^ a b c d e Page Module:Citation/CS1/styles.css has no content."Memantine Hydrochloride Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Archived from the original on 25 April 2019. Retrieved 3 March 2019.
  11. ^ a b c d Page Module:Citation/CS1/styles.css has no content."Memantine hydrochloride". British national formulary: BNF 76 (76 ed.). Pharmaceutical Press. 2018. pp. 303–304. ISBN 978-0-85711-338-2. OCLC 1050279948.
  12. ^ a b c d e f g h Page Module:Citation/CS1/styles.css has no content.del Río-Sancho S (2020). "Memantine and Alzheimer's disease". Diagnosis and Management in Dementia. Elsevier. pp. 511–527. doi:10.1016/b978-0-12-815854-8.00032-x. ISBN 978-0-12-815854-8.
  13. ^ a b c d e f Page Module:Citation/CS1/styles.css has no content.Herrmann N, Li A, Lanctôt K (April 2011). "Memantine in dementia: a review of the current evidence". Expert Opinion on Pharmacotherapy. 12 (5): 787–800. doi:10.1517/14656566.2011.558006. PMID 21385152.
  14. ^ a b c d e Page Module:Citation/CS1/styles.css has no content.Witt A, Macdonald N, Kirkpatrick P (February 2004). "Memantine hydrochloride". Nature Reviews. Drug Discovery. 3 (2): 109–110. doi:10.1038/nrd1311. PMID 15040575.
  15. ^ Page Module:Citation/CS1/styles.css has no content."Top 300 of 2023". ClinCalc. Archived from the original on 12 August 2025. Retrieved 12 August 2025.
  16. ^ Page Module:Citation/CS1/styles.css has no content."Memantine Drug Usage Statistics, United States, 2014 - 2023". ClinCalc. Retrieved 18 August 2025.
  17. ^ Page Module:Citation/CS1/styles.css has no content.Mount C, Downton C (July 2006). "Alzheimer disease: progress or profit?". Nature Medicine. 12 (7): 780–784. doi:10.1038/nm0706-780. PMID 16829947.
  18. ^ NICE review of technology appraisal guidance 111 January 18, 2011 Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): final appraisal determination Script error: No such module "webarchive".
  19. ^ Page Module:Citation/CS1/styles.css has no content.Page AT, Potter K, Clifford R, McLachlan AJ, Etherton-Beer C (October 2016). "Medication appropriateness tool for co-morbid health conditions in dementia: consensus recommendations from a multidisciplinary expert panel". Internal Medicine Journal. 46 (10): 1189–1197. doi:10.1111/imj.13215. PMC 5129475. PMID 27527376.
  20. ^ a b c Rossi S, editor. Australian Medicines Handbook 2006. Adelaide: Australian Medicines Handbook; 2006.
  21. ^ Page Module:Citation/CS1/styles.css has no content.McShane R, Westby MJ, Roberts E, Minakaran N, Schneider L, Farrimond LE, et al. (March 2019). "Memantine for dementia". The Cochrane Database of Systematic Reviews. 3 (3) CD003154. doi:10.1002/14651858.CD003154.pub6. PMC 6425228. PMID 30891742.
  22. ^ Page Module:Citation/CS1/styles.css has no content.van Dyck CH, Tariot PN, Meyers B, Malca Resnick E (2007). "A 24-week randomized, controlled trial of memantine in patients with moderate-to-severe Alzheimer disease". Alzheimer Disease and Associated Disorders. 21 (2): 136–143. doi:10.1097/WAD.0b013e318065c495. PMID 17545739.
  23. ^ Page Module:Citation/CS1/styles.css has no content.Schneider LS, Dagerman KS, Higgins JP, McShane R (August 2011). "Lack of evidence for the efficacy of memantine in mild Alzheimer disease". Archives of Neurology. 68 (8): 991–998. doi:10.1001/archneurol.2011.69. PMID 21482915.
  24. ^ Page Module:Citation/CS1/styles.css has no content.Chen R, Chan PT, Chu H, Lin YC, Chang PC, Chen CY, et al. (21 August 2017). Chen K (ed.). "Treatment effects between monotherapy of donepezil versus combination with memantine for Alzheimer disease: A meta-analysis". PLOS ONE. 12 (8) e0183586. Bibcode:2017PLoSO..1283586C. doi:10.1371/journal.pone.0183586. PMC 5565113. PMID 28827830.
  25. ^ Page Module:Citation/CS1/styles.css has no content."Dementia: assessment, management and support for people living with dementia and their carers". National Institute for Health and Care Excellence (NICE). 20 June 2018. Archived from the original on 12 August 2020. Retrieved 6 August 2020.
  26. ^ Page Module:Citation/CS1/styles.css has no content.Vogelbaum MA, Brown PD, Messersmith H, Brastianos PK, Burri S, Cahill D, et al. (February 2022). "Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline". Journal of Clinical Oncology. 40 (5): 492–516. doi:10.1200/JCO.21.02314. PMID 34932393.
  27. ^ Page Module:Citation/CS1/styles.css has no content.British National Formulary (47th ed.). London: BMA and the Royal Pharmaceutical Society of Great Britain. 2004. ISBN 978-0-85369-584-4.
  28. ^ a b Page Module:Citation/CS1/styles.css has no content.Morris H, Wallach J (2014). "From PCP to MXE: a comprehensive review of the non-medical use of dissociative drugs". Drug Testing and Analysis. 6 (7–8): 614–632. doi:10.1002/dta.1620. PMID 24678061.
  29. ^ Page Module:Citation/CS1/styles.css has no content.Swedberg MD, Ellgren M, Raboisson P (April 2014). "mGluR5 antagonist-induced psychoactive properties: MTEP drug discrimination, a pharmacologically selective non-NMDA effect with apparent lack of reinforcing properties". The Journal of Pharmacology and Experimental Therapeutics. 349 (1): 155–164. doi:10.1124/jpet.113.211185. PMID 24472725.
  30. ^ Page Module:Citation/CS1/styles.css has no content.Elbe D (2019). Clinical handbook of psychotropic drugs for children and adolescents (Tertiary source). Boston, MA: Hogrefe. pp. 366–369. ISBN 978-1-61676-550-7. OCLC 1063705924.
  31. ^ a b c d Page Module:Citation/CS1/styles.css has no content.Limapichat W, Yu WY, Branigan E, Lester HA, Dougherty DA (February 2013). "Key binding interactions for memantine in the NMDA receptor". ACS Chemical Neuroscience. 4 (2): 255–260. doi:10.1021/cn300180a. PMC 3751542. PMID 23421676.
  32. ^ a b c d e Page Module:Citation/CS1/styles.css has no content.Seeman P, Caruso C, Lasaga M (February 2008). "Memantine agonist action at dopamine D2High receptors". Synapse. 62 (2): 149–153. doi:10.1002/syn.20472. hdl:11336/108388. PMID 18000814.
  33. ^ Page Module:Citation/CS1/styles.css has no content.Spanagel R, Eilbacher B, Wilke R (September 1994). "Memantine-induced dopamine release in the prefrontal cortex and striatum of the rat--a pharmacokinetic microdialysis study". European Journal of Pharmacology. 262 (1–2): 21–26. doi:10.1016/0014-2999(94)90023-x. PMID 7813574.
  34. ^ Page Module:Citation/CS1/styles.css has no content.Peeters M, Maloteaux JM, Hermans E (June 2003). "Distinct effects of amantadine and memantine on dopaminergic transmission in the rat striatum". Neuroscience Letters. 343 (3): 205–209. doi:10.1016/S0304-3940(03)00398-7. PMID 12770697.
  35. ^ Page Module:Citation/CS1/styles.css has no content.Maskell PD, Speder P, Newberry NR, Bermudez I (December 2003). "Inhibition of human alpha 7 nicotinic acetylcholine receptors by open channel blockers of N-methyl-D-aspartate receptors". British Journal of Pharmacology. 140 (7): 1313–1319. doi:10.1038/sj.bjp.0705559. PMC 1574144. PMID 14645141.
  36. ^ a b Page Module:Citation/CS1/styles.css has no content.Ferrer-Acosta Y, Rodriguez-Massó S, Pérez D, Eterovic VA, Ferchmin PA, Martins AH (October 2022). "Memantine has a nicotinic neuroprotective pathway in acute hippocampal slices after an NMDA insult". Toxicology in Vitro. 84 105453. Bibcode:2022ToxVi..8405453F. doi:10.1016/j.tiv.2022.105453. PMC 10026604. PMID 35944748.
  37. ^ a b Page Module:Citation/CS1/styles.css has no content.Rammes G, Danysz W, Parsons CG (March 2008). "Pharmacodynamics of memantine: an update". Current Neuropharmacology. 6 (1): 55–78. doi:10.2174/157015908783769671. PMC 2645549. PMID 19305788.
  38. ^ Page Module:Citation/CS1/styles.css has no content.Cacabelos R, Takeda M, Winblad B (January 1999). "The glutamatergic system and neurodegeneration in dementia: preventive strategies in Alzheimer's disease". International Journal of Geriatric Psychiatry. 14 (1): 3–47. doi:10.1002/(SICI)1099-1166(199901)14:1<3::AID-GPS897>3.0.CO;2-7. PMID 10029935.
  39. ^ Page Module:Citation/CS1/styles.css has no content.Rogawski MA, Wenk GL (2003). "The neuropharmacological basis for the use of memantine in the treatment of Alzheimer's disease". CNS Drug Reviews. 9 (3): 275–308. doi:10.1111/j.1527-3458.2003.tb00254.x. PMC 6741669. PMID 14530799.
  40. ^ Page Module:Citation/CS1/styles.css has no content.Robinson DM, Keating GM (2006). "Memantine: a review of its use in Alzheimer's disease". Drugs. 66 (11): 1515–1534. doi:10.2165/00003495-200666110-00015. PMID 16906789.
  41. ^ Page Module:Citation/CS1/styles.css has no content.Xia P, Chen HS, Zhang D, Lipton SA (August 2010). "Memantine preferentially blocks extrasynaptic over synaptic NMDA receptor currents in hippocampal autapses". The Journal of Neuroscience. 30 (33): 11246–11250. doi:10.1523/JNEUROSCI.2488-10.2010. PMC 2932667. PMID 20720132.
  42. ^ a b Page Module:Citation/CS1/styles.css has no content.Parsons CG, Stöffler A, Danysz W (November 2007). "Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system--too little activation is bad, too much is even worse". Neuropharmacology. 53 (6): 699–723. doi:10.1016/j.neuropharm.2007.07.013. PMID 17904591.
  43. ^ Page Module:Citation/CS1/styles.css has no content.Lipton SA (October 2007). "Pathologically activated therapeutics for neuroprotection". Nature Reviews. Neuroscience. 8 (10): 803–808. doi:10.1038/nrn2229. PMID 17882256.
  44. ^ Page Module:Citation/CS1/styles.css has no content.Rammes G, Rupprecht R, Ferrari U, Zieglgänsberger W, Parsons CG (June 2001). "The N-methyl-D-aspartate receptor channel blockers memantine, MRZ 2/579 and other amino-alkyl-cyclohexanes antagonise 5-HT(3) receptor currents in cultured HEK-293 and N1E-115 cell systems in a non-competitive manner". Neuroscience Letters. 306 (1–2): 81–84. doi:10.1016/S0304-3940(01)01872-9. PMID 11403963.
  45. ^ a b c Page Module:Citation/CS1/styles.css has no content.Aracava Y, Pereira EF, Maelicke A, Albuquerque EX (March 2005). "Memantine blocks alpha7* nicotinic acetylcholine receptors more potently than n-methyl-D-aspartate receptors in rat hippocampal neurons". The Journal of Pharmacology and Experimental Therapeutics. 312 (3): 1195–1205. doi:10.1124/jpet.104.077172. PMID 15522999.
  46. ^ Page Module:Citation/CS1/styles.css has no content.Aracava Y, Pereira EF, Maelicke A, Albuquerque EX (March 2005). "Memantine blocks alpha7* nicotinic acetylcholine receptors more potently than n-methyl-D-aspartate receptors in rat hippocampal neurons". The Journal of Pharmacology and Experimental Therapeutics. 312 (3): 1195–1205. doi:10.1124/jpet.104.077172. PMID 15522999.
  47. ^ Page Module:Citation/CS1/styles.css has no content.Bali ZK, Bruszt N, Tadepalli SA, Csurgyók R, Nagy LV, Tompa M, et al. (5 February 2019). "Cognitive Enhancer Effects of Low Memantine Doses Are Facilitated by an Alpha7 Nicotinic Acetylcholine Receptor Agonist in Scopolamine-Induced Amnesia in Rats". Frontiers in Pharmacology. 10 73: 73. doi:10.3389/fphar.2019.00073. PMC 6371842. PMID 30804787.
  48. ^ Page Module:Citation/CS1/styles.css has no content.Buisson B, Bertrand D (March 1998). "Open-channel blockers at the human alpha4beta2 neuronal nicotinic acetylcholine receptor". Molecular Pharmacology. 53 (3): 555–563. doi:10.1124/mol.53.3.555. PMID 9495824.
  49. ^ Page Module:Citation/CS1/styles.css has no content.Gotti C, Clementi F (December 2004). "Neuronal nicotinic receptors: from structure to pathology". Progress in Neurobiology. 74 (6): 363–396. doi:10.1016/j.pneurobio.2004.09.006. PMID 15649582.
  50. ^ Page Module:Citation/CS1/styles.css has no content.Spanagel R, Eilbacher B, Wilke R (September 1994). "Memantine-induced dopamine release in the prefrontal cortex and striatum of the rat--a pharmacokinetic microdialysis study". European Journal of Pharmacology. 262 (1–2): 21–26. doi:10.1016/0014-2999(94)90023-x. PMID 7813574.
  51. ^ Page Module:Citation/CS1/styles.css has no content."Memantine Ki values". PDSP Ki Database. UNC. Archived from the original on 30 July 2022. Retrieved 30 July 2022.
  52. ^ Page Module:Citation/CS1/styles.css has no content.Peeters M, Romieu P, Maurice T, Su TP, Maloteaux JM, Hermans E (April 2004). "Involvement of the sigma 1 receptor in the modulation of dopaminergic transmission by amantadine". The European Journal of Neuroscience. 19 (8): 2212–2220. doi:10.1111/j.0953-816X.2004.03297.x. PMID 15090047.
  53. ^ Page Module:Citation/CS1/styles.css has no content."Pharms - Memantine (also Namenda): Erowid Exp: Main Index". erowid.org. Archived from the original on 7 November 2018. Retrieved 7 November 2018.
  54. ^ Page Module:Citation/CS1/styles.css has no content.Ragshaniya A, Kumar V, Tittal RK, Lal K (March 2024). "Nascent pharmacological advancement in adamantane derivatives". Archiv der Pharmazie. 357 (3) e2300595. doi:10.1002/ardp.202300595. PMID 38128028.
  55. ^ a b Page Module:Citation/CS1/styles.css has no content.Danysz W, Dekundy A, Scheschonka A, Riederer P (February 2021). "Amantadine: reappraisal of the timeless diamond-target updates and novel therapeutic potentials". Journal of Neural Transmission. 128 (2): 127–169. doi:10.1007/s00702-021-02306-2. PMC 7901515. PMID 33624170.
  56. ^ Page Module:Citation/CS1/styles.css has no content.Morozov IS, Ivanova IA, Lukicheva TA (May 2001). "Actoprotector and Adaptogen Properties of Adamantane Derivatives (A Review)". Pharmaceutical Chemistry Journal. 35 (5): 235–238. doi:10.1023/A:1011905302667.
  57. ^ Page Module:Citation/CS1/styles.css has no content.Gerzon K, Krumkalns EV, Brindle RL, Marshall FJ, Root MA (November 1963). "The Adamantyl Group in Medicinal Agents. I. Hypoglycemic N-Arylsulfonyl-N'-adamantylureas". Journal of Medicinal Chemistry. 6 (6): 760–763. doi:10.1021/jm00342a029. PMID 14184942.
  58. ^ Page Module:Citation/CS1/styles.css has no content.Elks J (2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer US. p. 432. ISBN 978-1-4757-2085-3. Retrieved 12 September 2024.
  59. ^ Page Module:Citation/CS1/styles.css has no content.Bormann J (August 1989). "Memantine is a potent blocker of N-methyl-D-aspartate (NMDA) receptor channels". European Journal of Pharmacology. 166 (3): 591–592. doi:10.1016/0014-2999(89)90385-3. PMID 2553441.
  60. ^ a b Page Module:Citation/CS1/styles.css has no content.Parsons CG, Danysz W, Quack G (June 1999). "Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist--a review of preclinical data". Neuropharmacology. 38 (6): 735–767. doi:10.1016/s0028-3908(99)00019-2. PMID 10465680.
  61. ^ Page Module:Citation/CS1/styles.css has no content.Wesemann W, Sontag KH, Maj J (1983). "[Pharmacodynamics and pharmacokinetics of memantine]" [Pharmacodynamics and pharmacokinetics of memantine]. Arzneimittel-Forschung (in Deutsch). 33 (8): 1122–1134. OCLC 115684407. PMID 6357202.
  62. ^ a b Page Module:Citation/CS1/styles.css has no content.Jackisch R, Link T, Neufang B, Koch R (1992). "Studies on the mechanism of action of the antiparkinsonian drugs memantine and amantadine: no evidence for direct dopaminomimetic or antimuscarinic properties". Archives Internationales de Pharmacodynamie et de Thérapie. 320: 21–42. PMID 1284458.
  63. ^ Page Module:Citation/CS1/styles.css has no content."Form 10-KSB For the fiscal year ended June 30, 1996". SEC Edgar. 30 September 1996. Archived from the original on 3 March 2017. Retrieved 5 February 2017. NTI-Children's license is included in the filing.
  64. ^ Page Module:Citation/CS1/styles.css has no content.Delevett P (9 January 2000). "Cash is king, focus is queen". Silicon Valley Business Journal. Archived from the original on 5 February 2017. Retrieved 5 February 2017.
  65. ^ Page Module:Citation/CS1/styles.css has no content.Staff (15 August 2000). "Lundbeck signs memantine licensing agreement for Merz+Co". The Pharma Letter. Archived from the original on 20 April 2016. Retrieved 6 April 2016.
  66. ^ Page Module:Citation/CS1/styles.css has no content."Namenda Sales Data". Drugs.com. February 2014. Archived from the original on 27 April 2019. Retrieved 23 January 2018.
  67. ^ Page Module:Citation/CS1/styles.css has no content."Evaluating Prescription Drugs Used to Treat: Alzheimer's Disease. Comparing Effectiveness, Safety, and Price" (PDF). Consumer Reports Health. May 2012. Archived (PDF) from the original on 5 September 2012. Retrieved 16 February 2015.
  68. ^ Page Module:Citation/CS1/styles.css has no content.Pollack A (15 September 2014). "Forest Laboratories' Namenda Is Focus of Lawsuit". The New York Times. Archived from the original on 10 February 2018. Retrieved 24 August 2017.
  69. ^ Page Module:Citation/CS1/styles.css has no content.Capati VC, Kesselheim AS (April 2016). "Drug Product Life-Cycle Management as Anticompetitive Behavior: The Case of Memantine". Journal of Managed Care & Specialty Pharmacy. 22 (4): 339–344. doi:10.18553/jmcp.2016.22.4.339. PMC 10398055. PMID 27023687.
  70. ^ Page Module:Citation/CS1/styles.css has no content."Actavis Confirms Appeals Court Ruling Requiring Continued Distribution of Namenda IR". Actavis. 22 May 2015. Archived from the original on 18 November 2017. Retrieved 24 August 2017.
  71. ^ Page Module:Citation/CS1/styles.css has no content.Gurrieri V (9 June 2015). "Actavis, Others Plotted To Delay Generic Namenda, Suit Says". Law360. Archived from the original on 24 August 2017. Retrieved 24 August 2017.
  72. ^ Page Module:Citation/CS1/styles.css has no content.LoBiondo GA (12 August 2015). "Second Circuit Denies Petition for Actavis Rehearing | David Kleban". Patterson Belknap Webb & Tyler LLP. Archived from the original on 24 August 2017. Retrieved 24 August 2017.
  73. ^ a b c d e Page Module:Citation/CS1/styles.css has no content.Morris H, Wallach J (2014). "From PCP to MXE: a comprehensive review of the non-medical use of dissociative drugs". Drug Testing and Analysis. 6 (7–8): 614–632. doi:10.1002/dta.1620. PMID 24678061.
  74. ^ Page Module:Citation/CS1/styles.css has no content.Heal DJ, Gosden J, Smith SL (November 2018). "Evaluating the abuse potential of psychedelic drugs as part of the safety pharmacology assessment for medical use in humans". Neuropharmacology. 142: 89–115. doi:10.1016/j.neuropharm.2018.01.049. PMID 29427652.
  75. ^ Page Module:Citation/CS1/styles.css has no content.Nicholson KL, Jones HE, Balster RL (May 1998). "Evaluation of the reinforcing and discriminative stimulus properties of the low-affinity N-methyl-D-aspartate channel blocker memantine". Behavioural Pharmacology. 9 (3): 231–243. OCLC 121220269. PMID 9832937.
  76. ^ Page Module:Citation/CS1/styles.css has no content.Natter J, Michel B (September 2020). "Memantine misuse and social networks: A content analysis of Internet self-reports". Pharmacoepidemiology and Drug Safety. 29 (9): 1189–1193. doi:10.1002/pds.5070. PMID 32602152.
  77. ^ a b c Page Module:Citation/CS1/styles.css has no content.Zdanys K, Tampi RR (August 2008). "A systematic review of off-label uses of memantine for psychiatric disorders". Progress in Neuro-Psychopharmacology & Biological Psychiatry. 32 (6): 1362–1374. doi:10.1016/j.pnpbp.2008.01.008. PMID 18262702.
  78. ^ Page Module:Citation/CS1/styles.css has no content.Dean RL, Hurducas C, Hawton K, Spyridi S, Cowen PJ, Hollingsworth S, et al. (September 2021). "Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder". The Cochrane Database of Systematic Reviews. 9 (9) CD011612. doi:10.1002/14651858.CD011612.pub3. PMC 8434915. PMID 34510411.
  79. ^ Page Module:Citation/CS1/styles.css has no content.Kleeblatt J, Betzler F, Kilarski LL, Bschor T, Köhler S (May 2017). "Efficacy of off-label augmentation in unipolar depression: A systematic review of the evidence". European Neuropsychopharmacology. 27 (5): 423–441. doi:10.1016/j.euroneuro.2017.03.003. PMID 28318897.
  80. ^ Page Module:Citation/CS1/styles.css has no content.Kishi T, Matsunaga S, Iwata N (2017). "A Meta-Analysis of Memantine for Depression". Journal of Alzheimer's Disease. 57 (1): 113–121. doi:10.3233/JAD-161251. PMID 28222534.
  81. ^ Page Module:Citation/CS1/styles.css has no content.Veronese N, Solmi M, Luchini C, Lu RB, Stubbs B, Zaninotto L, et al. (June 2016). "Acetylcholinesterase inhibitors and memantine in bipolar disorder: A systematic review and best evidence synthesis of the efficacy and safety for multiple disease dimensions". Journal of Affective Disorders. 197: 268–280. doi:10.1016/j.jad.2016.03.034. PMID 27010579.
  82. ^ Page Module:Citation/CS1/styles.css has no content.Bartoli F, Cavaleri D, Bachi B, Moretti F, Riboldi I, Crocamo C, et al. (November 2021). "Repurposed drugs as adjunctive treatments for mania and bipolar depression: A meta-review and critical appraisal of meta-analyses of randomized placebo-controlled trials". Journal of Psychiatric Research. 143: 230–238. doi:10.1016/j.jpsychires.2021.09.018. PMID 34509090.
  83. ^ Page Module:Citation/CS1/styles.css has no content.Hsu TW, Chu CS, Ching PY, Chen GW, Pan CC (June 2022). "The efficacy and tolerability of memantine for depressive symptoms in major mental diseases: A systematic review and updated meta-analysis of double-blind randomized controlled trials". Journal of Affective Disorders. 306: 182–189. doi:10.1016/j.jad.2022.03.047. PMID 35331821.
  84. ^ Page Module:Citation/CS1/styles.css has no content.Andrade C (2017). "Memantine as an Augmentation Treatment for Schizophrenia: Limitations of Meta-Analysis for Evidence-Based Evaluation of Research". The Journal of Clinical Psychiatry. 78 (9): e1307–e1309. doi:10.4088/JCP.17f11998. PMID 29178686.
  85. ^ Page Module:Citation/CS1/styles.css has no content.Kishi T, Ikuta T, Oya K, Matsunaga S, Matsuda Y, Iwata N (August 2018). "Anti-Dementia Drugs for Psychopathology and Cognitive Impairment in Schizophrenia: A Systematic Review and Meta-Analysis". The International Journal of Neuropsychopharmacology. 21 (8): 748–757. doi:10.1093/ijnp/pyy045. PMC 6070030. PMID 29762677.
  86. ^ Page Module:Citation/CS1/styles.css has no content.Zheng W, Zhu XM, Zhang QE, Cai DB, Yang XH, Zhou YL, et al. (July 2019). "Adjunctive memantine for major mental disorders: A systematic review and meta-analysis of randomized double-blind controlled trials". Schizophrenia Research. 209: 12–21. doi:10.1016/j.schres.2019.05.019. PMID 31164254.
  87. ^ a b c d Page Module:Citation/CS1/styles.css has no content.Lange KW, Riederer P (January 1994). "Glutamatergic drugs in Parkinson's disease". Life Sciences. 55 (25–26): 2067–2075. doi:10.1016/0024-3205(94)00387-4. PMID 7997066.
  88. ^ Page Module:Citation/CS1/styles.css has no content.Fischer PA, Jacobi P, Schneider E, Schönberger B (July 1977). "[Effects of intravenous administration of memantine in parkinsonian patients (author's transl)]" [Effects of intravenous administration of memantine in parkinsonian patients]. Arzneimittel-Forschung (in German). 27 (7): 1487–1489. PMID 332193.{{cite journal}}: CS1 maint: unrecognized language (link)
  89. ^ Page Module:Citation/CS1/styles.css has no content.Schneider E, Fischer PA, Clemens R, Balzereit F, Fünfgeld EW, Haase HJ (June 1984). "[Effects of oral memantine administration on Parkinson symptoms. Results of a placebo-controlled multicenter study]" [Effects of oral memantine administration on Parkinson symptoms. Results of a placebo-controlled multicenter study]. Deutsche Medizinische Wochenschrift (in Deutsch). 109 (25): 987–990. doi:10.1055/s-2008-1069311. PMID 6734455.
  90. ^ Page Module:Citation/CS1/styles.css has no content."Memantine - Children's Medical Center Corporation/Merz Pharma". AdisInsight. 5 November 2023. Retrieved 12 September 2024.
  91. ^ a b c Page Module:Citation/CS1/styles.css has no content.Olivares D, Deshpande VK, Shi Y, Lahiri DK, Greig NH, Rogers JT, et al. (July 2012). "N-methyl D-aspartate (NMDA) receptor antagonists and memantine treatment for Alzheimer's disease, vascular dementia and Parkinson's disease". Current Alzheimer Research. 9 (6): 746–758. doi:10.2174/156720512801322564. PMC 5002349. PMID 21875407.
  92. ^ a b Page Module:Citation/CS1/styles.css has no content.Merello M, Nouzeilles MI, Cammarota A, Leiguarda R (1999). "Effect of memantine (NMDA antagonist) on Parkinson's disease: a double-blind crossover randomized study". Clinical Neuropharmacology. 22 (5): 273–276. PMID 10516877.
  93. ^ Page Module:Citation/CS1/styles.css has no content.Gonzalez-Latapi P, Bhowmick SS, Saranza G, Fox SH (October 2020). "Non-Dopaminergic Treatments for Motor Control in Parkinson's Disease: An Update". CNS Drugs. 34 (10): 1025–1044. doi:10.1007/s40263-020-00754-0. PMID 32785890.
  94. ^ Page Module:Citation/CS1/styles.css has no content.Onofrj M, Frazzini V, Bonanni L, Thomas A (2016). "Chapter 3 - Amantadine and antiglutamatergic drugs in the management of Parkinson's disease". In Gálvez-Jiménez N, Fernandez HH, Espay AJ, Fox SH (eds.). Parkinson's Disease: Current and Future Therapeutics and Clinical Trials. Cambridge medicine. Cambridge University Press. p. 16. ISBN 978-1-107-05386-1. Retrieved 12 September 2024.
  95. ^ Page Module:Citation/CS1/styles.css has no content.Vidal EI, Fukushima FB, Valle AP, Villas Boas PJ (January 2013). "Unexpected improvement in levodopa-induced dyskinesia and on-off phenomena after introduction of memantine for treatment of Parkinson's disease dementia". Journal of the American Geriatrics Society. 61 (1): 170–172. doi:10.1111/jgs.12058. hdl:11449/74234. PMID 23311565.
  96. ^ Page Module:Citation/CS1/styles.css has no content.Danysz W, Gossel M, Zajaczkowski W, Dill D, Quack G (October 1994). "Are NMDA antagonistic properties relevant for antiparkinsonian-like activity in rats?--case of amantadine and memantine". Journal of Neural Transmission. Parkinson's Disease and Dementia Section. 7 (3): 155–166. doi:10.1007/BF02253435. PMID 7710668.
  97. ^ Page Module:Citation/CS1/styles.css has no content.Rabey JM, Nissipeanu P, Korczyn AD (1992). "Efficacy of memantine, an NMDA receptor antagonist, in the treatment of Parkinson's disease". Journal of Neural Transmission. Parkinson's Disease and Dementia Section. 4 (4): 277–282. doi:10.1007/BF02260076. PMID 1388698.
  98. ^ a b Page Module:Citation/CS1/styles.css has no content.Grosso Jasutkar H, Oh SE, Mouradian MM (January 2022). "Therapeutics in the Pipeline Targeting α-Synuclein for Parkinson's Disease". Pharmacological Reviews. 74 (1): 207–237. doi:10.1124/pharmrev.120.000133. PMC 11034868. PMID 35017177.
  99. ^ a b Page Module:Citation/CS1/styles.css has no content.McFarthing K, Rafaloff G, Baptista M, Mursaleen L, Fuest R, Wyse RK, et al. (2022). "Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2022 Update". Journal of Parkinson's Disease. 12 (4): 1073–1082. doi:10.3233/JPD-229002. PMC 9198738. PMID 35527571.
  100. ^ Clinical trial number NCT03858270 for "Inhibition of α-synuclein Cell-cell Transmission by NMDAR Blocker, Memantine" at ClinicalTrials.gov
  101. ^ Page Module:Citation/CS1/styles.css has no content.Ballard C, Kahn Z, Corbett A (October 2011). "Treatment of dementia with Lewy bodies and Parkinson's disease dementia". Drugs & Aging. 28 (10): 769–777. doi:10.2165/11594110-000000000-00000. PMID 21970305.
  102. ^ Page Module:Citation/CS1/styles.css has no content.Szeto JY, Lewis SJ (2016). "Current Treatment Options for Alzheimer's Disease and Parkinson's Disease Dementia". Current Neuropharmacology. 14 (4): 326–338. doi:10.2174/1570159x14666151208112754. PMC 4876589. PMID 26644155.
  103. ^ Page Module:Citation/CS1/styles.css has no content.Wang HF, Yu JT, Tang SW, Jiang T, Tan CC, Meng XF, et al. (February 2015). "Efficacy and safety of cholinesterase inhibitors and memantine in cognitive impairment in Parkinson's disease, Parkinson's disease dementia, and dementia with Lewy bodies: systematic review with meta-analysis and trial sequential analysis". Journal of Neurology, Neurosurgery, and Psychiatry. 86 (2): 135–143. doi:10.1136/jnnp-2014-307659. PMID 24828899.
  104. ^ Page Module:Citation/CS1/styles.css has no content.Marin RS, Wilkosz PA (2005). "Disorders of diminished motivation". The Journal of Head Trauma Rehabilitation. 20 (4): 377–388. doi:10.1097/00001199-200507000-00009. PMID 16030444.
  105. ^ Page Module:Citation/CS1/styles.css has no content.Chong T, Husain M (2016). "The role of dopamine in the pathophysiology and treatment of apathy". Motivation - Theory, Neurobiology and Applications. Progress in Brain Research. Vol. 229. pp. 389–426. doi:10.1016/bs.pbr.2016.05.007. ISBN 978-0-444-63701-7. PMID 27926449.
  106. ^ Page Module:Citation/CS1/styles.css has no content.Sepehry AA, Sarai M, Hsiung GR (May 2017). "Pharmacological Therapy for Apathy in Alzheimer's Disease: A Systematic Review and Meta-Analysis". The Canadian Journal of Neurological Sciences. Le Journal Canadien des Sciences Neurologiques. 44 (3): 267–275. doi:10.1017/cjn.2016.426. PMID 28148339.
  107. ^ Page Module:Citation/CS1/styles.css has no content.Harrison F, Aerts L, Brodaty H (November 2016). "Apathy in Dementia: Systematic Review of Recent Evidence on Pharmacological Treatments". Current Psychiatry Reports. 18 (11) 103: 103. doi:10.1007/s11920-016-0737-7. hdl:1959.4/unsworks_41850. PMID 27726067.
  108. ^ Page Module:Citation/CS1/styles.css has no content.Andrade C (February 2022). "Methylphenidate and Other Pharmacologic Treatments for Apathy in Alzheimer's Disease". The Journal of Clinical Psychiatry. 83 (1). doi:10.4088/JCP.22f14398. PMID 35120284.
  109. ^ Page Module:Citation/CS1/styles.css has no content.Azhar L, Kusumo RW, Marotta G, Lanctôt KL, Herrmann N (February 2022). "Pharmacological Management of Apathy in Dementia". CNS Drugs. 36 (2): 143–165. doi:10.1007/s40263-021-00883-0. PMID 35006557.
  110. ^ Page Module:Citation/CS1/styles.css has no content.Müller T, Riederer P, Kuhn W (February 2023). "Aminoadamantanes: from treatment of Parkinson's and Alzheimer's disease to symptom amelioration of long COVID-19 syndrome?". Expert Review of Clinical Pharmacology. 16 (2): 101–107. doi:10.1080/17512433.2023.2176301. PMID 36726198.
  111. ^ Page Module:Citation/CS1/styles.css has no content.Frontera JA, Guekht A, Allegri RF, Ashraf M, Baykan B, Crivelli L, et al. (November 2023). "Evaluation and treatment approaches for neurological post-acute sequelae of COVID-19: A consensus statement and scoping review from the global COVID-19 neuro research coalition". Journal of the Neurological Sciences. 454 120827. doi:10.1016/j.jns.2023.120827. PMID 37856998.
  112. ^ Page Module:Citation/CS1/styles.css has no content.Beach SR, Gomez-Bernal F, Huffman JC, Fricchione GL (September 2017). "Alternative treatment strategies for catatonia: A systematic review". General Hospital Psychiatry. 48: 1–19. doi:10.1016/j.genhosppsych.2017.06.011. PMID 28917389.
  113. ^ Page Module:Citation/CS1/styles.css has no content.Obregon DF, Velasco RM, Wuerz TP, Catalano MC, Catalano G, Kahn D (July 2011). "Memantine and catatonia: a case report and literature review". Journal of Psychiatric Practice. 17 (4): 292–299. doi:10.1097/01.pra.0000400268.60537.5e. PMID 21775832.
  114. ^ Page Module:Citation/CS1/styles.css has no content.Graziane J, Davidowicz E, Francis A (2020). "Can Memantine Improve Catatonia and Co-occurring Cognitive Dysfunction? A Case Report and Brief Literature Review". Psychosomatics. 61 (6): 759–763. doi:10.1016/j.psym.2020.05.026. PMID 32665151.
  115. ^ Page Module:Citation/CS1/styles.css has no content.Dessus-Gilbert ML, Nourredine M, Zimmer L, Rolland B, Geoffray MM, Auffret M, et al. (23 July 2024). "NMDA antagonist agents for the treatment of symptoms in autism spectrum disorder: a systematic review and meta-analysis". Frontiers in Pharmacology. 15 1395867. doi:10.3389/fphar.2024.1395867. PMC 11295073. PMID 39108755.
  116. ^ Page Module:Citation/CS1/styles.css has no content.Brignell A, Marraffa C, Williams K, May T (August 2022). "Memantine for autism spectrum disorder". The Cochrane Database of Systematic Reviews. 8 (8) CD013845. doi:10.1002/14651858.CD013845.pub2. PMC 9409629. PMID 36006807.

Further reading

Page Template:Refbegin/styles.css has no content.

Lua error in package.lua at line 80: module 'Module:Navbox/configuration' not found. Lua error in package.lua at line 80: module 'Module:Navbox/configuration' not found. Lua error in package.lua at line 80: module 'Module:Navbox/configuration' not found. Lua error in package.lua at line 80: module 'Module:Navbox/configuration' not found. Lua error in package.lua at line 80: module 'Module:Navbox/configuration' not found. Template:Ionotropic glutamate receptor modulators Template:Nicotinic acetylcholine receptor modulators Lua error in package.lua at line 80: module 'Module:Navbox/configuration' not found. Lua error in package.lua at line 80: module 'Module:Navbox/configuration' not found.Lua error in package.lua at line 80: module 'Module:Navbox/configuration' not found. Lua error in mw.title.lua at line 404: bad argument #2 to 'title.new' (unrecognized namespace name 'Portal'). Lua error in package.lua at line 80: module 'Module:Authority control/config' not found.

Retrieved from "http://cosmopedia.co/index.php?title=Memantine&oldid=736649"